Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China
National Nature Science Foundation of China, the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, and Beijing Xisike Clinical Oncology Research Foundation.
Authors
- Zengjun Li (ORCID: https://orcid.org/0000-0003-0787-8089)
- Rui Lyu (ORCID: https://orcid.org/0000-0003-0302-7615)
- Dehui Zou (ORCID: https://orcid.org/0000-0002-8135-4913)
- Lugui Qiu (ORCID: https://orcid.org/0000-0002-8752-0644)
- Gang An (ORCID: https://orcid.org/0000-0003-4922-4614)
- Shuhui Deng
- Shuhua Yi (ORCID: https://orcid.org/0000-0002-6291-812X)
- Xiantao Liu
- Yaozhong Zhao (ORCID: https://orcid.org/0000-0002-4597-9182)
- Yuting Yan (ORCID: https://orcid.org/0000-0002-9355-2984)
- Wenjie Xiong (ORCID: https://orcid.org/0000-0003-1207-6291)
- Ying Sun (ORCID: https://orcid.org/0000-0002-5888-2929)
- Qi Wang (ORCID: https://orcid.org/0000-0002-5287-6050)
- Wei Liu (ORCID: https://orcid.org/0000-0002-1773-5156)
- Hui Wang (ORCID: https://orcid.org/0000-0002-3470-4159)
- Liang Huang (ORCID: https://orcid.org/0000-0003-4850-6732)
- Tingyu Wang (ORCID: https://orcid.org/0000-0001-5000-7890)
- Yan Xu (ORCID: https://orcid.org/0009-0009-1445-252X)
Institutions
- Chifeng University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Chifeng Municipal Hospital (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103688
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00